Windlas Biotech - Pure play CDMO currently at ~1.1x sales

I came across this podcast on Windlas Biotech

I hope you find it useful.

dr.vikas

3 Likes

14-15% stake will be holding by Mr. Utpal seth, erstwhile mgr at RARE enterprises …not by RARE ENTERPRISES of Rakesh jhunjhunwala

1 Like

Superb space within CDMO

4 Likes

Please do mention the source of this information.
dr.vikas

2 Likes

Good read with red flag : Windlas Biotech | IPO Analysis | SPTulsian.com

1 Like

I am sharing an in depth blog on Indian CDMOs

I hope you find it useful

dr.vikas

2 Likes

5 Likes

For existing investors, what is the potential return expectation from the stock? The management has guided for ₹1,000 crore in revenue once the capex is fully operational, along with a 2-3% improvement in margins. In a best-case scenario, the company could achieve a PAT of ₹110 crore with 15% ebidta margins. Based on this, what price-to-earnings (P/E) multiple would be reasonable to attribute to the stock?

2 Likes

You can take the Industry median of around 35x but PAT margin can’t get 15% that would be 10% max, 15% is EBITDA margin guidance

2 Likes